Zymeworks Form 144: 31,641 shares proposed sale
Zymeworks filed a Form 144 reporting a proposed sale of 31,641 shares of common stock on 02/17/2026, tied to the exercise of options and an exercise-and-sell-to-cover transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Zymeworks filed a Form 144 reporting a proposed sale of 31,641 shares of common stock on 02/17/2026, tied to the exercise of options and an exercise-and-sell-to-cover transaction.
The excerpt also lists prior sales by Leone Patterson of 6,832 shares on 01/12/2026 for $154,905.35 and 117,255 shares on 02/13/2026 for $2,706,749.60.
Insights
Form 144 documents a proposed resale tied to option exercise and sell-to-cover.
The filing lists a proposed sale of 31,641 shares on 02/17/2026, described as an exercise of options with an exercise-and-sell-to-cover method. This is a routine disclosure under resale rules and identifies past reported dispositions by a named holder.
Timing and settlement mechanics beyond the stated are not shown; cash‑flow treatment to the issuer is not specified in the excerpt. Subsequent SEC filings or broker confirmations would show completion details.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does ZYME's Form 144 report?
Does the Form 144 indicate proceeds go to Zymeworks?
What is the primary transaction date shown?
Are the listed past sales part of the current offering?
AI-generated analysis. How Rhea-AI works. Not financial advice.